New study results from the STREAM trial.
"... a three-center prospective phase 2 single-arm trial ... of men with Gleason 7-10 PC and PSA recurrence within 4 yr of RP {prostatectomy} ranging from 0.2 to 4.0 ng/dl, no prior hormonal therapy, and no radiographic evidence of metastases. We enrolled 38 men; 37 completed therapy ..."
"Six months of ADT with 160 mg/d enzalutamide and 66 Gy RT to the prostate bed."
"The primary endpoint of 2-yr {progression-free survival} was 65% ... versus 51% ... in a trial of men with similar eligibility treated with salvage RT and adjuvant docetaxel."
"The 3-yr {progression-free survival} was 53%."
"Salvage RT with enzalutamide and ADT following RP for men with PSA recurrent high-risk PC is safe and demonstrates encouraging efficacy, warranting prospective controlled phase 3 trials of ADT with or without potent androgen receptor inhibition in this curative-intent {!!!} setting."
***
Implies that improved progression-free survival translates to improved overall survival. However, the addition of 6 months of XTANDI may change the nature of surviving PCa cells. Half of the men progressed within 3 years. How did prior XTANDI use affect their overall survival?
-Patrick